80 Antimicrobial Use and Stewardship

Saturday, March 20, 2010: 2:00 PM-3:30 PM
International North (Hyatt Regency Atlanta)
Type: Oral
Moderators:
Neil Fishman and John McGowan, MD
2:00 PM
662
Early Experience with the Statewide Rollout of a Computerized Antimicrobial Approval System
Karin A. Thursky, MBBS, MD, Victorian infectious diseases service royal melbourne hospital; Marion B. Robertson, B, Pharm, Victorian infectious diseases service royal melbourne hospital; Susan B. Luu, B, Pharm, Victorian infectious diseases service royal melbourne hospital; Michael J. Richards, MBBS, MD, Victorian infectious diseases service royal melbourne hospital; Duncan McKenzie, B, Pharm, Royal Hobart Hospital; Tara Anderson, Royal Hobart Hospital; Kirsty L. Buising, MBBS, MD, MPH, Victorian infectious diseases service royal melbourne hospital
2:15 PM
663
ESAC Point Prevalence Survey of Antibiotic Use in 134 European Hospitals in 2009
Peter Zarb, M.Phil, Mater Dei Hospital; Brice Amadeo, MSc, Inserm; Arno Muller, PhD, University of Antwerp; Vanessa Vankerckhoven, PhD, University of Antwerp; Peter Davey, Professor, Division of Community and Population Sciences and Education; Herman Goossens, MD, PhD, University Hospital of Antwerp
2:30 PM
664
Antimicrobial Stewardship: Lessons from Pandemic Influenza
Ari Robicsek, MD, NorthShore University HealthSystem; Gene Schwartz, NorthShore University HealthSystem; Rumi Semer, NorthShore University HealthSystem; Lance R. Peterson, NorthShore University HealthSystem
2:45 PM
665
Unnecessary use of fluoroquinolone antibiotics in hospitalized patients
Nicole L. Werner, MS, Case Western Reserve University; Steven F. Greer, MD, Metrohealth Medical Center; Michelle T. Hecker, MD, Metrohealth Medical Center; Ajay K. Sethi, PhD, University of Wisconsin-Madison; Curtis J. Donskey, MD, Louis Stokes Cleveland VA Medical Center
3:00 PM
666
Antimicrobial Stewardship: The Cost of Discontinuing a Program
Harold Standiford, MD, University of Maryland Medical Center; Graeme Forrest, MBBS, Portland VA Medical Center; Shannon Chan, pharm, D, Al duPont Hospital for Children; Elizabeth Weekes, pharm, D, Rocky Mountain Poison and Drug Center; Megan Tripoli, BA, University of Maryland Medical Center
3:15 PM
667
Measuring Antimicrobial Utilization of Gram-Negative (GN) Agents in the Era of Pharmacodynamic Dosing: Days of Therapy (DOT) Are Significantly Different from Defined Daily Doses (DDD)
Christine J. Kubin, PharmD, Columbia University; NewYork-Presbyterian Hospital; E. Yoko Furuya, MD, MS, Columbia University